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Introduction: The rate of switch from first-line to second-line regimen and number patients 
taking second line ART is increasing from time to time, and in Ethiopia 1.5% HIV patients on 
ART are on second line regimen. Though some studies based in Ethiopia investigate the 
outcomes of first-line HIV treatment; to date, no study has been done regarding second line 
treatment. This study aims to anticipate the rate of second line regimens failure and predictors 
and thereby to inform respective stakeholders and assist in planning for the need of third line 
regimens in the future.                                                                   
Objective: To assess second line Antiretroviral treatment failure and predictors among adults 
in northwest Ethiopia. 
Methods:  Institution based retrospective follow up study was conducted at University of 
Gondar, Flege Hiwot referral and Debretabor Hospitals from March 30, 2015 to May 18, 2015 
among 356 clients in the age of 15 and above. The data were collected from patient charts, 
computer soft copies and registries. Life table was used to estimate the cumulative survival. 
Both bi-variable and multivariable Cox proportional hazards models were used to identify 
predictor of failure. 95% confidence level was used. 
Result: Out 356 participants, 198 (55.62%) are males and mean age of patients at switch was 
36.13 + 8.9 years. Study subjects were followed for a minimum of 6 months and the median 
follow up period was 32.25 months (IQR=37.8 months).A total 67(18.82%) patients develop 
treatment failure. The incidence rate of failure was 61.7/1000 person year and the cumulative 
probabilities of survival at 12, 24, and 60, months were 0.94, 0.86, and 0.7654 respectively. 
Furthermore 62.7 % of failures were occurred within the first two year of follow up. Being in 
WHO clinical stage IV(AHR=2.6, 95%CI:1.3,   5.14), CD4 count <100 cells/mm3 (AHR=1.78, 
95%CI: 1.03, 3.076), age 50 and above(AHR=2.32, 95%CI: 1.016, 5.32) change in weight 
(AHR=0.916, 95%CI:0.88, 0.955), and switching in the calendar year September 2103 to 
October 2014( AHR=5.178454 , 95%CI: 1.16, 23.07)were significant and independent  
predictors of failure.  
Conclusion and recommendations: The rate of treatment failure was comparable as 
compared to many sub-Saharan African studies and majority of failures were occurring in the 
first two years after switch. Hence close follow up of patients in the early period after switch 
and provision of an alternative third line regimen should be considered.  
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1. INTRODUCTION 
1.1 statement of the problem 
Human Immunodeficiency Virus (HIV) is a global challenge for the past three decades. 
Globally in 2013, 35 million were living with HIV (1)with an estimated 24.7 million people 
living with HIV in sub-Saharan Africa, nearly 71% of the global total(1, 2) and in Ethiopia 
the HIV prevalence among adults age 15-49 in the 2011 Ethiopia Demographic Health 
Survey(EDHS) is 1.5 percent (3) with an estimated incidence of 35,002 and death of 
52,405 by 2014(4) (5). 
Since 1995,  Anti retroviral treatment (ART) saved the lives of millions globally and has 
substantially decreased morbidity and mortality in people living with HIV/AIDS (PLWHA) 
(6). Based on United Nations Program on HIV/AIDS (UNAIDS) report of 2014 globally 
as many as 13,950,296 people were accessing ART(2). For the 2013-14 year, the 
Federal Ministry of Health of Ethiopa(FMOH) reported that 1047 health facilities 
providing ART, 805,948 PLWHA who were ever enrolled in HIV/AIDS care, 492,649 
PLWHA who had ever started ART, and 344,344 current ART users (7)and 1.5 % of 
these were on second line treatment. Amhara regional state comprises the highest 
number with 102,088 current ART users. In Ethiopia  since the beginning of free 
ART,from 2005  to 2013, death duet to HIV/AIDS decreased by 63%(2). 
Most patients begin treatment on a standard first-line regimen. The first-line treatment 
consists of a combination of two nucleoside/nucleotide reverse transcriptase inhibitors 
(NRTI)  with one non-nucleoside reverse transcriptase inhibitors (NNRTI); second-line 
treatment then utilizes two NRTIs not previously used in that particular patient for their 
first line treatment, with the addition of one protease inhibitors (PI) (8, 9). Treatment 
failure of this initial Highly Active Anti retroviral treatment (HAART) regimen is a 
common, though not inevitable, event(10) . 
Second-line regimens are used when first-line drugs no longer protect the immune 
system, as measured by a patient’s CD-4 cell count, HIV viral load, or clinical picture. 
Standard combinations do not work for everyone, particularly if they have contracted a 
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drug-resistant strain of the virus(11). Though first-line medications are frequently 
effective, viral mutation and drug resistance(12) do occur and are followed by treatment 
failure, which requires switching to a second-line regimen. However , many patients in 
sub-Saharan Africa remain on failing first-line regimens(13), and the rate of switch is 
increasing from time to time(14),(15). 
According to different studies showed, switching patients to second-line regimens 
reduces mortality(14), increases viral suppression and improves immune 
reconstitution(16, 17) ,increases life expectancy (18) and decrease the spread of drug 
resistance (19). Although the magnitude of patients taking second line ART is small (20) 
due to delay in switching from first-line(21, 22) as well as challenges in drug availability 
and adherence, it needs a great attention.  
However, some studies conducted in different sub Saharan countries, to our knowledge, 
no studies regarding second-line ART failure have been conducted in Ethiopia 
particularly in the study area. We proposed to measure the treatment failure and its 
predictors after shifts to second-line regimens, which is the last treatment option for 
those who have failed first-line treatment. 
 Therefore this study aims to anticipate the rate and predictors of second line regimen 
failure, to inform respective stakeholders and assist in planning for the challenge in HIV 
control strategy in the future. 
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1.2. Literature review 
1.2.1 Treatment failure of second line ART 
Once the patients who are living with HIV/AIDS are shifted from first line regimen to 
second line regimen, there are different fates that will be expected from the patient. As 
said before, after some follow up period a patient may die, LTFU, develop treatment 
failure, he or she may transferred to another facility or they might alive in care. 
Different studies assessed treatment failure in different way with respect to clinical, 
Immunological and/or virological criteria According to an observational study done in 
Asia among those who used secondline ART for more than six months, the rates of 
treatment failure was 8.8 per 100 patient/years were (95% confidence interval: 7.1 to 
10.9)(23).  A to multi-centered study conducted in Asia and Africa, recorded failure of 
any type was 19% with an overall Incidence of 195 per 1000 person-years and 119 
(18.8%) met World Health Organization failure criteria after a median 11.9 months 
following the start of second-line therapy, and at 1 and 2 years of second-line start,12% 
and 28% of patients, respectively, had recorded failure of any type(24). In another 
prospective follow up study conducted in six sub Saharan Africa countries to determine 
re-suppression of drug-resistant HIV-1 by second-line ART treatment failure was 
assessed by different approaches and , (13.9%) experienced virological failure, 12.1% 
of patients developed immunological failure and 6.3 percent experienced clinical 
failure(25).  
A retrospective follow p study done in rural South Africa among patients switched due to 
virological failure from first line treatment, the rate of treatment failure was 25.1%,  
(26) and in the same setting with another study, treatment failure at 24 month was 
25%(27)  
According to a meta-analysis of different studies including adults and children who used 
secondline ART in developing countries, pooled treatment failure assessed by 
virological failure, was 21.79% at six months, 23.06% at 12 months, 26.65% at 24 
months, and 38.02% at 36 months (28). Another observational cohort study done in 
   
3 
 
South Africa among second line ART users which assessed treatment failure by 
virological way revealed that, the rate of failure every six month at each point ranges 
from 3% to 16% and by the end of 12 month after switch it was 13%(29). A prospective 
follow up study conducted in Nigeria to assess viral mutation of second-line ART, by 
virological monitoring, treatment failure was 10% at the end of the study(30). 
As shown by different studies done, death after switch has also a great contribution with 
a different range of rate. In Georgia,  10.7 percent (31) ,In another study conducted in 
sub-Saharan Africa, Asia and Latin America  8 percent of patients died after a median 
follow-up of 5 month(32, 33), in a study done in Zambia and Malawi with an incidence of 
19.2 (15.2–23.9) per 1000 person-years (14) in another study involved eleven sub-
Saharan African countries with a rate of 5.0 per 100 person-years(13).As well as lost to 
follow up(LTFU) is also an important fate with 16.16% in South Africa revealed (34), 
7.8% in a cohort study done in Sub-Saharan Africa (25).  
In managing patients who switched to second line ART, transfer out and patient 
retention has considerable implications. As per  a study done in south Africa, retention 
in care was 74.04 percent (34). A study done in rural south Africa  to assess second line 
ART outcome, retention rate at the end of follow-up whilst on second-line ART was 
72.8%  and 7.9% of them were transferred out(TO) (26). Additionally, According to a 
Prospective Cohort study on second-Line ART in Sub-Saharan Africa TO was 1.6%(25). 
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1.2.2 Predictors of second-line ART outcome 
Multiple studies done in Asia and Africa have shown that age and sex are significant 
socio-demographic determinants in the occurrence failure among patients taking first 
line and second-line ART and especially among secondline users, being old was a 
significant predictor of failure (23, 35-37) as well as being male was also being male 
predicts failure particularly in first line users(35, 36, 38). According to different a study 
done in sub India, and a negative change in body weight also had a significant effect on 
treatment failure (39).  
According to multi-centered study conducted in Asia and Africa, and also the same 
study done in south Africa, treatment failure rates increased with lower CD4 cell counts 
when second-line therapy was started(24, 29). According to studies done in China, 
South Africa, rural Southern Africa involving three countries among adult first line ART 
users, lower baseline CD4 cell count was also a major predictor of death(36, 38, 40).  
In accordance with  a retrospective follow up study of the evaluation of five-year 
outcomes of initial patients treated in Botswana’s National ART Program and  Other 
study conducted in rural Southern Africa among adult ART users, being at advanced 
clinical stage was a significant predictor of failure and death (25, 36, 41).Further more 
as presents in a systematic review and meta analysis on the outcome of second line 
ART in developing countries, as the duration of ART intake increases treatment failure 
rate also increases(28). 
In a cohort study to compare the tenofovir (TDF) containing and non containing second-
line ART in Zambia and South Africa; mortality was lower among patients taking TDF 
containing regimen as compared to those without TDF(42).In another cohort of patients 
in Asia and Africa, failure rates were lower in those who changed 2 nucleoside reverse 
transcriptase inhibitors (NRTIs) at the time of second line ART than those changed one 
NRTI(24). Prophylaxis for opportunitisic infection also affects loss to follow-up. In a 
cohort follow-up study done at Mizan-Aman General Hospital in Ethiopia, among 
patients on first-line ART who were not on isoniazid (INH) prophylaxis were at higher 
risk of loss to follow up (33). A two-year prospective follow up study in the Oromiya 
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Region showed that cotrimoxazole prophylaxis therapy (CPT) at or before ART initiation 
was associated  also with lower mortality.(43) 
Conceptual frame work 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.  Conceptual framework of secondline ART outcome  
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1.3 Justification of the study 
Second-line HAART regimens are indicated for patients who are forced to discontinue 
their initial treatment regimen as a consequence of treatment failure, drug toxicity or 
poor adherence.  However, their outcome is not yet studied specially in our country 
despite that living with HIV longer is one of the global strategies. Provision of ARV 
treatment by itself is not enough to control the problems of HIV treatment unless we 
monitor and evaluate its outcome through scientific research. Though some studies 
based in Ethiopia investigate the outcomes of first-line HIV treatment; no study, to our 
knowledge, has been done regarding second line treatment. Since second line 
treatments are the next and the only options as per to the Ethiopian ART treatment 
guideline, it is crucial and timely to know the rate of failure and determinant factors of 
second line treatment. This study will help to further evaluate the progress in Ethiopia’s 
strategy against HIV/AIDS, to anticipate the effect of second-line regimens, to inform 
respective stakeholders about the current state of the uptake of second-line ART, and to 
assist in planning for the possible need of future, third line regimens. 
. 
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2. OBJECTIVE 
2.1 General objective  
• To determine second line Antiretroviral treatment failure and predictors  among 
adults in northwest Ethiopia, 2015  
2.2 Specific objective 
• To determine second line Antiretroviral treatment failure among adults in 
northwest Ethiopia, 2015  
• To identify predictors of second line Antiretroviral treatment failure among adults 
in northwest Ethiopia, 2015  
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3. METHODS 
3.1 Study design  
Institution based retrospective follow up study was conducted. 
3.2 Study area and period 
The study was conducted in University of Gondar Hospital, Felege Hiwot referral 
Hospital and Debre-tabor Hospital from March 30, 2015 to May 18, 2015. Patients who 
switched between september 2006 to October 2014 were included and followed until 
April 2015.  
University of Gondar Referral Hospital HIV care clinic was one of the areas. It is located 
in North Gondar administrative zone, Amhara National Regional state, which is far from 
about 750 km Northwest of Addis Ababa (the capital city of Ethiopia). According to the 
2007 population and housing census report, the total population size of Gondar town 
was estimated to be 206,987. Currently Gondar town has one Referral Hospital and five 
government Health Centers. University of Gondar Referral Hospital is a teaching 
Hospital which serves more than five million people of the North Gondar zone and 
peoples of the neighboring zones.  The HIV care service of the Hospital was initiated in 
2005 and has three clinics: Adult ART clinic, Pediatric ART clinic, and VCT clinic.  
The second area was Felege Hiwot Referral Hospital which is located in Bahirdar town, 
Amhara National Regional State, Ethiopia. Bahirdar is the capital city of Amhara 
National Regional State and it is located 562 kms from Addis Ababa and 180 kms from 
Gondar. The hospital founded in 1963 and served for a catchment population of 5 to 7 
million. Currently, apart from other services, Felege Hiwot Referral Hospital is providing 
HIV chronic care (both pre ART and ART) services for clients who attend chronic care 
and treatment services. The ART clinic has 6 outpatient rooms (OPD), one VCT, one 
pharmacy, one laboratory and one adherence counseling rooms. A total of 9 nurses, 3 
general practitioners, 4 data clerks, 3 pharmacists and 15 adherence counselors are 
currently working. Since 2005 in which the hospital started ART, 16314 adults and 1383 
pediatrics patients are enrolled. Currently 5401 adults are actively following their 
treatment. 
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The third study area was Debretabor Hospital which is located in Debretabor 665 kms 
from Addis Ababa. It serves for a catchment population of a round 2million. Currently, 
apart from other services, Debretabor Hospital is providing HIV chronic care (both pre 
ART and ART) services for clients who attend chronic care and treatment services. It 
has two OPDs, one pharmacy and one laboratory. Currently in the clinic, three nurses, 
two general practitioners, four adherence counselors and two data clerks are working. 
3.3 Source and study population  
The target population for this study includes all HIV positive adults age15 years and 
above who are taking second ling ART in northwest Ethiopia. 
3.4 Inclusion and Exclusion Criteria 
Inclusion Criteria 
 All HIV positive adults (age >=15 years) on second line ART and switched from 
first line regimen and took second line ART for at least six months.  
Exclusion criteria 
 Patients who have less than two follow up CD4 count, transferred in after switch 
and who had incomplete baseline information were excluded. 
3.5 Sample size and sampling procedures 
In a prospective follow up study conducted in six sub Saharan Africa countries (Kenya, 
Nigeria, South Africa, Uganda, Zambia, and Zimbabwe) to determine re-suppression of 
Drug-Resistant HIV-1 by second-line ART after first-line failure, immunological failure 
was diagnosed in 12.1 percent,  and 6.3 percent experienced clinical failure.  Death due 
to HIV occurred in 4.5percent. 1.6 percent of subjects transferred out of the study and 
another 7.8 percent were lost to follow-up. Finally, a WHO clinical staging of 4 at the 
time of switch was a significant pedictor of failure with Hazards Ratio of 5.25 (25). 
Based on this similar literature, the sample size for this study is calculated as follows: 
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Outcome  proportion Level of confidence Margin of 
error  
Final 
sample size 
immunological 
failure  
12.1% 95% 4% 
 
255 
clinical failure 6.3% 95% 3% 
 
252 
death  4.5%  95% 3% 
 
183 
lost to follow-
up  
7.8% 95% 3% 
 
307 
 
Predictors Assumptions Proportions  Hazard 
ratio 
Sample size 
WHO clinical 
stage 
4(failure) 
Power=90% 
CI= 95% 
1:1 Ratio 
P1= 31.8% 
P2 = 67.567% 
2.03 158 
 
According to the sample size calculation, we used the largest of all which is 307 and 
since the number of patients in the three sites who fulfilled was 356, we incorporated 
the remaining 49 cards to increase the power of the study. Out 356, 29 were from Debre 
tabor hospital, 151 from university of Gondar hospital and 176 from Felege Hiwot 
referral hospital.  
3.6 Variables of the study 
Dependent variable 
Treatment failure of secondline ART and its time of occurrence  
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Explanatory variables 
Socio-demographic characteristics: Age, sex 
Clinical characteristics: WHO clinical staging, CD4 count at shift of ART, length of 
time on first-line ART, change in weight, presence of OI, calendar year of starting 
second-line ART 
Treatment related: Drug regimen, OI prophylaxis, CPT, INH, history of first line 
modification, treatment duration, number of changed NRTIs, and drug side effect. 
3.7 Operational definitions 
Second-line regimens: is a boosted PI-based regimen, following a first-line regimen of 
one NNRTI and two NRTIs. 
Censored:  An individual followed second line ART for more than six months and still 
on follow-up or transferred out but not developed treatment failure.  
Clinical failure: New or recurrent clinical event indicating severe immunodeficiency. 
WHO clinical stage 4 condition and certain WHO clinical stage 3 conditions (such as 
pulmonary TB and severe bacterial infections which may also indicate treatment failure) 
after 6 months of effective treatment. 
Immunological failure: Failure is defined if at least one of the criteria below is fulfilled: 
follow up CD4 count fall to or below baseline values, a 50% fall from on treatment peak 
value, or persistent CD4 levels below 100 cells/mm3. 
Death: Death from any cause in a patient on second -line ART. 
Transferred out - Those patients who are transferred to other health care facilities. 
Transferred in - Those patients who are transferred from other facilities and accepted 
by the hospital. 
Loss to follow up (LTFU): Is defined in a patient who is not receiving ARTs refill for a 
period of 3 months or longer from the last clinic attendance, and is not yet classified as 
‘dead’ or ‘transferred-out’.  
Treatment failure: was considered as a composite outcome of immunological failure, 
clinical failure, death and LTFU. If a patient had one of the four outcomes, he/she was 
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considered as having treatment failure. This is because as showed from different 
studies, the cause of majority of deaths is treatment failure, as well as most of patients 
who lost from follow up are those having treatment failure and majority them will died 
after being lost(13, 39, 44, 45).  
3.8. Data collection procedures  
Data collectors: A standardized data extraction check-list was prepared in English. 
Four health officers and 5 BSc nurses who have experience in working at ART  clinic 
were participated in the data collection process after half day theoretical and half day 
practical training given. The data clerks and card room workers of the three hospital 
were also supported them by identifying the cards of patients.  
Data collection procedure:  Before going to collect data, the records to be reviewed 
(both baseline and follow-up records) were identified by their medical registration/card 
number. Then, together with the data clerk working at each respective ART clinic, data 
collectors reviewed and extracted data from patient charts and registries. For those 
cards which have incomplete information, the computer data base were used to 
supplement the information provided in the cards. Cards of patients switched from 
September 2006 up to October 2014 were included. 
Data quality control 
Training on the objective of the study and how to review the documents as per the data 
extraction format was given to data collectors and the supervisor for one day prior to 
data collection. The data extraction checklist was pre-tested for consistency of 
understanding the review tools and completeness of data items on 10 charts and the 
necessary adjustments were made on the final data extraction format.  The Principal 
Investigator, with two other supervisors who are MPH candidate having clinical 
background and MSc candidate in Tropical infectious disease and HIV Medicine, 
supervised the overall process. The filled formats were checked for completeness by 
the Principal Investigator and/or the supervisors on daily basis.    
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3.9. Data processing and analysis 
The data was entered in to EPI info version 7 and transferred to STATA version 12.0 for 
analysis. Descriptive and summary statistics was carried out. We observed rate of 
failure of the composite outcome (treatment failure) and each of the outcomes 
separately. Person time at risk was measured starting from the time of switch until each 
patient ends the follow up. Patients who switched from September 2006 up to October 
2014 were included in the analysis. Life table was used to estimate the cumulative 
survival of patients and Log rank tests were used to compare survival curves between 
the different categories of the explanatory variables. Schoenfeld residuals test(both 
global and scaled) and  -Ln(-ln) graph was used to check cox proportional hazard 
assumption. Both bivariate and multi variate Cox proportional hazards models were 
used to identify predictor variables. Variables having p value 0.2 or less in the bi-
variable analysis were fitted in to the multi variable model.  Ninety five percent 
confidence interval of hazard ratio (HR) was computed and variables having p - value 
less than 0.05 in the multi variable Cox proportional hazards model were considered as 
significantly associated with the dependent variable.  
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4. ETHICAL CONSIDERATIONS 
Ethical clearance was obtained from Institutional Review Board of Institute of Public 
Health, CMHS, and University of Gondar. After that support letter from Amhara 
Regional State Health Bureau for Felege Hiwot and DebreTabor hospitals was written 
and permission letter were also obtained from the hospitals administration and the ART 
focal persons in the three hospitals. Names and unique ART numbers of patients were 
not being included during data collection. 
Moreover data collectors and supervisors were professionals who have experience of 
working in ART clinics.  
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5. RESULTS 
5.1 Baseline socio-demographic characteristics of the study subjects 
Out of 356 participants, 198(55.62 were males, the mean age of the patients was 36.13 
+ 8.9 years, 167(46.91%) of the participants were in the age range between 30 to 39 
years and 260 (73.03%) were urban dwellers (Table 1).   
Table 1:- Baseline socio-demographic characteristics of HIV positive adults on second 
line ART at  University of Gondar, Flege Hiwot referral and Debretabor Hospitals, 
September 1st, 2006 – April 8th, 2015. 
 
Variable Frequency Percent (%) 
Age 15-29 78 21.91        
30-39 167 46.91       
40-49 82 23.03 
>50 29 8.15 
Total 356 100.00 
Sex Male 198 55.62 
Female 158 44.38 
Total 356 100.0 
Marital 
status 
 
Unmarried 154   43.26       
Married 157 44.10    
Not recorded 45 12.64   
Total 356 100.00 
Residence Urban 260 73.03 
Rural 76 21.35 
Not recorded 20 5.62 
Total 549 100.0 
Religion Orthodox 297 83.43 
Muslim 15 4.21 
Protestant 6 1.69 
Not recorded 38 10.67 
Total  356 100.00 
Educational status    
 No education 75 21.07 
 Primary 75 21.07 
 Secondary 105 29.49 
 Tertiary 54 15.17 
 Not recorded 47 13.2 
 Total 356 100.00 
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5.2 Baseline clinical and immunological status of the study subjects 
At start of first line ART, most of the patients, 326 (91.57%) were eligible for ART 
because of their WHO clinical staging and out of them 176(49.44%) were eligibly by 
both clinical and immunological (CD4 count) criteria. At the beginning of first line 
treatment 306(86%) start ART at advanced stage of the disease i.e. WHO clinical stage 
III and IV  Regarding the functional status at first line ART start, majority 237(66.57%) 
were working and more than half of the study participants 213(59.8%), were having 
absolute CD4 count below 100 cells/milliliter.   
Nearly half 162(45.51%) of the study subjects start first line ART with NRTI backbone of 
AZT based regimen followed by D4T, 133(37.36 %) and TDF, 61(17.13)  and also NVP 
was NNRTI drub being taken by majority  257(72.2%) of the study subjects.  
For 118(33.15%) of participants, first drug regimen was substituted and the majority 
102(86.44%) modified only once and drug side effect was the reason for most of the 
regimen modification 82(70.7%) followed by TB 24 (20.7%). 
The median time of stay on first line regimen was 42.56 months with an IQR of 37.78 
months. Around 121(34%) of participants had previous history of TB treatment before 
switch to secondline ART. Up on switch to secondline ART, 210(59%) participants had 
recorded viral load and out of them 177(84.3%) had virological failure.  Majority of the 
participants 331(93%) had also immunological failure at switch(Fig 2).  
 
 
4.78%
C
G
F
D B
E
37.08%
1.4%
40.45%
6.46%
0.84%
13.76%
A
E = Drug toxicityA= Immuno, virologic and clinical failure
B= clinical failure only F = immuno-clinical failure
C= immunologic and virologic failure G= immunologic failure only
D= virologic failure only
Figure2. Reasons of switch to secondline ART, at University of Gondar, Flege Hiwot referral 
and Debretabor Hospitals, September 1st, 2006 – April 8th, 2015. 
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At switch to second-line ART, majority of the patients were on WHO clinical stage III. 
The mean weight of participants at baseline were 52.45±10.84, more than half 
206(57.87%) of the patients were taking TDF based secondline regimen and majority 
289(81.18%) were taking ritonavir boosted lopinavir (Table 2). 
Table 2:- Baseline and follow up clinical and immunological characteristics at switch of 
HIV positive adults on second line ART at University of Gondar, Felege Hiwot referral 
and Debretabor Hospitals, September 1st, 2006 – April 8th, 2015. 
Variable Category Frequency Percent (%) 
WHO clinical stage T stage I/II 127 35.67 
T stage III 172 48.31 
T stage IV 57 16.01 
Total 356 100.00 
Functional Status at 
second line ART 
start 
Working 298 83.71 
Ambulatory 35 9.83 
Bedridden 23 6.46 
Total  356 100.00 
Number of Changed 
NRTI  
 
None  19 5.31 
One  217 60.96 
Two 120 33.71 
Total 356 100.00 
Protease inhibitor LPV/r 289 81.18 
ATV/r 64 17.98 
NFV 3 0.84 
Total 356 100.00 
NRTI backbone  TDF 206 57.87 
ABC 102 28.65 
AZT 41 11.52 
Others(d4t, ddi) 7 1.97 
Total 356 100.00 
CD4 Count  at switch <100 cells/mm
3 122 62.36 
>=100 cells/mm3 134 37.64 
Total  356 100.00 
CPT Yes  306 85.96 
No 50 14.04 
Total 356 100.00 
INH Prophylaxis Yes 33 9.27 
No 323 90.73 
Total 356 100.00 
During the follow up period 24(6.74%) participants developed OI’s other than those 
which classified in the clinical failure category. Some 18(5.06%) of the partcipants had 
also modified their second line treatment mainly due to drug out of stock12(66.67%). 
Recorded drug adverse effect were present in 23 (6.46%) of the partcicpants.  
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5.3 outcome of secondline ART Treatment 
Study subjects were followed for a minimum of 6 months and a maximum of 104.467 
months after switched to secondline ART and the median follow up period was 32.25 
months (IQR=37.8 months).  
A total of 67(18.82%) patients developed treatment failure and among them 24(35.82%) 
were immunological failure, 11(16.41%) clinical failure, 21(31.34%) death, and 
11(16.41%) were lost to follow up. The remaining outcomes such as: transfer out and 
remaining on active follow up were, 24(6.74%), and 265(74.44%) respectively.                                                                  
Regarding the time of failure, 19 (28.3%) and 42(62.69%) of failures were reported 
within the first and second years of follow up respectively and the remaining 25(37.3%) 
of failures were recorded after third year of follow up. Study subjects were followed for 
different period of observation and total person time of observation was 1085.111 
person-years (13021.33 person-months). There were a total of 67 failures and this 
makes the risk of failure after switch to secondline ART 67/1085.11 = 61.74 treatment 
failures per 1000 person years of observation. As well when we see it separately, for 
immunological failure, 24/1085.11=22.1 per 1000 person years , for clinical failure 
11/1085.11 =10/1000 person year,  for the 21 deaths, and the risk of death becomes 19 
deaths/1000 person years and also the risk of lost to follow up becomes 11/1085.11 = 
10/1000 person year.  
As discussed earlier, for estimation of survival probability; treatment failure, death and 
lost to follow up were used as a composite outcome and were considered as failure and 
the model was fitted by using three of the outcomes as an event with a total of 67 
observed events.  The cumulative probabilities of survival at 12, 24, 60, and 96 months 
after switched to secondline ART were 0.94, 0.86, 0.7654, and 0.5772.  
The overall median CD4 count was 79 with IQR of 118, for treatment failure was 67 
cells/mm3  with an IQR of 91 and 82 cells/mm3  with an IQR of 122 for those who 
became censored at the end of the study. 
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Table 3: Outcome status of study subjects at the end of follow up with respect to their 
baseline socio-demographic and clinical characteristics of HIV positive adults on second 
line ART at University of Gondar, Felege Hiwot referral and Debretabor Hospitals, 
September 1st, 2006 – April 8th, 2015. 
 
 Outcomes at the end of follow up (Number (%)) 
Variable 
     Alive Dead LTFU 
Immunolo
gical 
failure 
Clinical 
failure Transfe
r out 
Total 
Age        
 15-29 56(21.13) 7(33.33) 2(18.2) 4(16.67) 4(36.36) 5(20.8) 78(21.9) 
 30-39 131(49.43) 10(47.62) 4(36.3) 7(29.17) 5(45.45) 10(41.7) 167(46.9) 
  40-49 62(23.4) 2(9.52) 2(18.2) 9(37.5) 1(9.09) 6(25) 82(23) 
 >=50 16(6.04) 2(9.52) 3 (27.3) 4(16.67) 1(9.09) 3(12.5) 29(8.2) 
Sex        
 Male 148(55.8) 10(47.6) 6(54.5) 15(62.5) 3(27.27) 16(66.7) 198(55.6) 
 Female 117(44.2) 11(52.4) 5(45.5) 9(37.5) 8(44.38) 8(33.3) 158(44.4) 
Functional status at switch       
 working  227(85.6%) 16(76.2) 7(636) 19(79.2) 9(81.82) 20(83.3) 298(83.7) 
 Ambulatory   27 (10.2) 0(00.00) 3(27.3) 3(12.5) 1(9.09) 76(4.2) 35(9.8) 
 Bedridden     11(4.2) 5(23.81) 1(9.1) 2(8.3) 1(9.09) 3(12.5) 23(6.5) 
CPT        
 On CPT 224(8.5) 18(85.7) 9(81.8) 22(91.7) 10(90.9) 23(95.8) 306(86) 
 Not on CPT 41(15.5) 3(14.3) 2(18.2) 2(8.3) 1(9.1) 1(4.2) 50(14) 
WHO staging        
 I or II 97(36.6) 4(19.0) 3(27.3) 8(33.3) 5(45.45) 10(4.7) 127(35.7) 
 III 133(50.2) 11(52.4) 4(36.4) 10(41.7) 4(36.36) 10(4.7) 172(48.3) 
 IV 35(13.2) 6(28.6) 4(36.4) 6(25) 2(18.18) 4(16.6) 57(16.0) 
CD4 count as switch        
 <100 159(60) 16(66.67) 8(72.7) 16(66.7) 6(54.55) 19(66.7) 222(62.4) 
 >=100 106(40) 8(33.3) 3(27.3) 8(33.3) 5(45.45) 8(33.3) 134(37.6) 
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Fig 3:- Kaplan Meir survival curve of HIV positive adults on second line ART at 
University of Gondar, Felege Hiwot referral and Debretabor Hospitals, September 1st, 
2006 – April 8th, 2015. 
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5.4 Predictors of secondline ART outcome 
Log rank (Mantel-Henszel Cox) test of equality of survival for the different categories of 
explanatory variables: age, presence of immunological failure at switch, and CD4 were 
significantly associated with treatment failure. 
Among median follow up period for those who have CD4 count<100 was 17 months 
with an IQR of 32.4 months where as for those whose CD4 count>=100 was 37.03 
months with an IQR of 43.7 months. At the end of 24 and 60 months the survival of 
those whose CD4 count<100 was 83.86& and 72, 3 % respectively (Figure 3).  
 
 
 
 
Fig 4:- Kaplan Meir survival curve by CD4 count at switch of HIV positive adults on 
second line ART at University of Gondar, Felege Hiwot referral and Debretabor 
Hospitals, September 1st, 2006 – April 8th, 2015. 
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Cox regression analysis 
As can be noted from the findings of bi-variable Cox regression analysis, switching in 
the calendar year September 2013 to October 2014, change in weight, CD4 count 
<100cells/mm3(change in cd4 count),  and being in WHO clinical stage IV  were 
predictors treatment failure. 
Consequently, in the multivariate Cox regression, to controls the undesirable effects of 
confounding variables, all variables which had p value less than 0.2 in the bi-variable 
analysis were included and a total of nine variables fitted in the model. Switching in the 
calendar year September 2013 to October 2014, change in weight(decrease in body 
weight), CD4 count <100cells/mm3 at switch, being in WHO clinical stage IV at base 
line,  and  age category 50 years and above were independent  predictors of treatment 
failure (the composite outcomes). But sex, INH prophylaxis, NRTI back bone at first line 
ART start and type of protease inhibitor being used at switch were not statistically 
significant. 
Accordingly, being in WHO stage IV was 2.58 times higher risk than being in stageI/II   
(AHR = 2.58, 95% CI: 1.3, 5.14). Those individuals who have weight increment at the 
end of follow up as compared to the base line has a good outcome and for a unit 
increase in weight in kilogram the risk of developing the outcome decreased by 8.4% 
(AHR= 0.916,95%CI:0.88, 0 .955). Individuals in the age range 50 and above were 2.32 
times at high risk than those individuals in the age group between 15 to 29 (AHR= 2.32, 
95%CI: 1.0166, 5.32). Having CD4 count <100 cells/mm3 at baseline increases the risk 
of developing the outcome  1.78 times as compared to those who have CD4 cont 100 
and more(AHR=1.78, 95%CI:1.031, 3.07). Calender year of switch has also a significant 
effect and those who stated ART by 2013/20144 were 5.178  times at higher risk as 
compared to those who switched by 2008 and before(AHR= 5.178, 95%CI:1.162    
23.076)(Tabl4). 
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 Table 4:- Multivariate Cox regression analysis of predictors of secondline ART 
outcome of adult  HIV positive University of Gondar, at Felege Hiwot referral and 
Debretabor hospitals, September 1st, 2006 – April 8th, 2015 
Variable Survival status Crude HR 
(95% CI) 
Adjusted HR 
(95% CI) Event censored 
Age     
 15-29 17 61 1  1 
 30-39 26 141 0.69(0 .376, 1.28) 0 .75(0.398, 1.4) 
 40-49 14 68 0.764(0.376,1.5) 0.81(0.39,1.68) 
 >=50 10 19 1.84(0.84, 4.024) 2.326(1.016,5.324) 
Sex     
 Male 34 164 0.84(0.52,1.37) * 
 Female 33 125 1  
INH Prophylaxis      
 Yes 3 30 2.27(0.712,7.22) * 
 No 64 259 1  
WHO clinical T staging at switch     
 I/II 20 107 1  
 III 29 143 0.845(0.47,1.49) 0.96(0 .52, 1.745) 
 IV 18 39 1.59(0.83, 3.04) 2.58(1.297, 5.14) 
Calendar year at switch     
 Sept 2006 to Aug 2008 6 18 1 1 
 Sept 2008 to Aug 2011 37 105 2.07(0.78,5.5) 2.06(0.719,5.915) 
 Sept 2011 to Aug 2013 14 104 1.53(0.51,4.57) 1.324(0.393,4.463) 
 Sept 2013 to Oct 2014 10 62 4.45(1.43, 13.8) 5.178(1.162,23.076) 
CD4 cell count      
 <100 cells/mm3 47 175 1.76(1.01,2.9) 1.78(1.03, 3.077) 
 >=100cells/mm3 20 114 1  
NRTI at first line ART 
start 
  
  
 D4T  29 104 1  
 AZT 15 137 0.86(0 .5,1.47) * 
 TDF 13 48 1.8(0.916,  3.56) * 
 
* Non significant from the multivariate Cox regression  
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6. DISCUSSION 
As defined by the composite outcome, immunological failure, clinical failure, death and 
lost are considered as treatment failure. According to this study treatment failure was 
67/356(18.8% (95%CI:   14.74%, 22.9%). When we see each of the outcomes 
separately, at the end of the follow up, 24(6.74 %(95%CI: 4.1%,9.36%)) developed 
immunological failure, 11(3.09%(95%CI: 1.28%, 4.9%)) developed clinical failure, 
21(5.9% 95%CI:3.44%, 8.36%)) died, 11(3.09%(95%CI: CI:1.28%, 4.9%)) lost to follow 
up, 24(6.74 %(95%CI: 4.1%,9.36%)) transferred out to another facility and the 
remaining 265(74.44%(95%CI: 69.8%, 79%) were alive.  
In our case, treatment failure was18.8% (95%CI: 14.74%, 22.9%) which is consistent 
with multi-centered study conducted in Asia and Africa having 19% failure at the end of 
follow up and with also a meta analysis having a range of outcomes (28). But it is lower 
than a retrospective follow up study done in rural South Africa among patients switched 
due to virological failure from first line treatment having treatment failure of 25.1%, (26) 
and in the same setting with another study having treatment failure at 24 month of 25% 
unlike ours which was 11.8% at 24 months(27) and it is also lower than another 
observational cohort study done in South Africa having the rate of failure of 13% by the 
end of 12 month after switch while ours was 5.34% at the end of 12 month of follow 
up(29).Even if the variation is minimal, it might be occur due to difference in approach in 
which, they were included patients who switched due to virological failure at unlike ours 
in which patients switched by different reasons. These patients who switched by 
virological failure might be debilitated at the start of secondline ART and that might 
affect their outcome. The other reason is that as different studies showed patients who 
had higher viral load at switch are at higher risk of viral mutation and drug resistance, 
and they will end up with failure. 
But our finding is higher than the studies done in six sub Saharan Africa countries in 
which they assessed by different approaches and according to their result(13.9%) 
experienced virological failure, 12.1% of patients developed immunological failure and 
6.3 percent experienced clinical failure(25), a study conducted in Nigeria by virological 
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monitoring having treatment failure of 10% at the end of the study(30). The difference 
might be explained by difference of classification since in our case we considered those 
immunologically, clinically failed, dead and lost as a failure. Furthermore, variation in 
setting and scope of the studies has also non-negligible effect. 
Regarding the incidence of failure, we found that 61.74 (95%CI: 48.6, 78.45) failures per 
1000 person year and it is consistent with a study done in Asia among those who used 
secondline ART in which the incident  rates of treatment failure was 88 (95% CI: 71 to 
109)per 1000 patient/years (23). But it is lower than a to multi-centered study conducted 
in Asia and Africa, with an overall Incidence of 195 per 1000 person-years e(24) and 
which might be due to the occurrence of higher failure in the early phase of switch and 
the difference might because of having longer follow up in our case. 
Transfer out to another setting was 6.74 %(95%CI: 4.1%,9.36%) and it is similar with a 
study done in rural south Africa  to 7.9% south Africa 4.57 % (26) (34)but it is lower than 
another study done in sub Saharan countries having TO of 1.6% (25) which can be 
explained by to shorter period of follow up they had in which many patients might not 
leave the facilities. Retention in care in our case was 74.44 %(95%CI: 69.8%, 79%) and 
it is similar with studies done in different sub-Saharan African countries  (25, 26). 
  
Being in the WHO clinical stage IV increases the risk of treatment failure 2.58(95% CI: 
1.297, 5.144) as compared to those in stage I&II at switch and also it increases the risk 
of failure 2.7(95%CI: 1.4, 5.2) as compared to being in stage III. This finding is 
consistent with studies in Malawi and in Sub-Saharan Africa (46). This might be due to 
the fact that those patients who had advanced disease are at higher risk of drug 
resistance, viral mutation and having an advanced opportunistic disease which further 
compromises their immunity and that might compromise their response to treatment 
after switch. 
Having lower CD4 count (<100) is also the other predictor of failure which increases the 
rate of failure by 1.78(95%CI: 1.03, 3.077). This is consistent with studies done in 
Thailand, Malawi, and South Africa (24, 29, 46). This might be due to patients who had 
very low CD4 count are labile to have different opportunistic diseases and the added 
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burden of these diseases further complicate their response and they might end up with 
failure and/or death. 
Those participants in the age category of 50 or more are 2.87(95%CI: 1.224, 6.747) 
times, 3.11(955CI: 1.44, 6.7) and 2.3263 (95%CI: 1.0166, 5.32) times at higher risk of 
failure than those in the age group between 40 to 49, 30 to 39 and 15 to 29 respectively. 
This is consistent with a study done in Asia(23).  This can be explained by decreasing of 
immunity in the elderly, vulnerability to chronic co-morbidities and also those patients in 
this age group were those who took medications for longer period of time and it might 
be associated with drug resistance and poor adherence caused by longer in take. 
A positive change in weight at the end of follow up as compared to baseline was a 
significant predictor of failure and for a unit increment of body weight in kilo gram, the 
risk of failure will decrease by 8.4%(AHR=0.95%CI:0.88,0.955).This might be consistent 
with studies which considered BMI (46). This might be explained by the consideration of 
weight gain as an indicator of good response to treatment.  
Those patients who switched in the calendar year September 2013 until October 2014 
were also 5.18(95%CI: 1.16, 23.076) times at higher risk of failure than those who 
switched before September 2008. This also can be explained by the fact that majority of 
those who switched recently are patients who were taking ART medication for longer 
period of time and that can cause viral mutation and drug resistance. More over this 
clients might be delayed on failing first line regimen and that might compromise their 
response after switch. 
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7. LIMITATIONS AND STRENGTHS  
 
The big limitations of this study is that data is collected from secondary source, it suffers 
from data incompleteness especially for follow up values which the study faces difficulty 
to see clinical and immunological responses of patients.  
Especially missing of some patient cards might cause survivor bias due to the hospitals 
dispose cards which are not actively being used by patients, and this might under 
estimate our outcome. 
Considering treatment failure as a composite outcome of immunological failure, clinical 
failure, dead and lost might inflate our finding. 
Strength of the study: the study was conducted in three big hospitals which increase its 
representativeness and also the longer duration of follow up period is good to have 
adequate number of events.  
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8. CONCLUSIONS 
 Treatment failure was comparable as compared to many sub-Saharan studies.  
 Most of the failures occurred during the first two years after switch and decreased 
after the third year of switch. 
 Being in WHO clinical stage IV, CD4 count<100, change in weight, Age category 50 
or more and switching in the calendar year 2014 were found to be predictors of 
treatment failure and an alternative third line ART should be considered for those 
who are on failing regimen. 
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9. RECOMMENDATIONS 
1. To health care providers managing HIV patients 
 Careful follow up and monitoring of patients on secondline ART need to be 
strengthened 
 To focus on regular nutritional assessment and support of patients  
 Especial care and support should be given for the elderly ART users. 
2.  To governmental and nongovernmental organizations  
 To strengthen careful follow up and regular viral load monitoring of patients on 
secondline ART  
 To find a possible way to start third line alternative for failing patients. 
3. To researchers 
 Prospective follow up study with virological monitoring is strongly 
recommended to come up with a strong evidence 
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11. Annexes 
Data collection Check list   
This checklist is prepared for the collection of socio-demographic, clinical, immunological, treatment and outcome related information that are important for the assessment of outcome and predictors of 
second line antiretroviral therapy in University of Gondar Hospital, Felege Hiwot referral Hospital and Debre Tabor Hospital. All this information will be retrieved from the clients ART and pre-ART 
registration book and from individual patient card without mentioning the name of clients. This information will be collected by health care providers (BSc nurse or Health Officer) possibly working in 
the ART clinic of the hospitals.  Contact Information   Adino Tesfahun  Tel  +251-918-068614 Mr.  Tadesse Awoke Tel: +251-910-173308 Dr. Mamo Wubshet    Tel:+251-912-180307 
Part I: Baseline variables  
S.No Variables  Categories       
101.  Hospital/Facility        
102.  Patient_MRN number       
103.  Age at enrollment ____years      
104.  Date of enrollment  
--------/------/-----------------(dd/mm/yy) 
    
105.  Gender  1 Female            2 Male     
106.  Address  Zone__________  Woreda______  Kebele_______   
107.  Marital status  1. Single               2. Married              3.Divorced        4. Widowed      5. Separated   
108.  Education  1.No education 2.Elementary   3 .Secondary  4 .Tertiary    
109.  Occupation  1.Unemployed      2.Government      3.Non government    4. Private      5 .Other        
110.  Religion 1. Orthodox 2. Muslim 3. Protestant 4. Catholic 5. Others 
111.  Care giver relation  1 Father/Mother        2 Son/daughter       3 brother/sister        4 other relative      5  Spouse    6. No care giver  
112.  Pastopportunistic 
infections at enrollment 
   1  Yes               2. No        
If yes, Specify(list all) _______________ 
 
113.  TB treatment history at 
enrollment 
1. Yes      2. No 3. Not recorded  
If yes date -----------------             Treatment outcome-------------- 
114.  Number of house hold ________persons      
115.  Disclosure status  1. Spouse  2.  Relatives 3. Child (ren) 4. Parents 5. Siblings                    6. Other 7.No 
116.  Substance use  1 Tobacco 2. Alcohol 3. Khat            4. None    
117.  First line ART start date   
------/----------/------------(dd/mm/yyyy) 
   
118.  Baseline  Weight  ___________kgm       
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119.  Baseline  Height  ___________cm       
120.  Baseline CD4 count _________      
121.  Baseline WHO stage  1 Stage I       2. Stage II        3. Stage III       4. Stage IV   
122.  Baseline  Functional 
status  
1 Working         2. Ambulatory     3. Bedridden    
123.  Reasons of eligibility for 
ART  
1. Clinical  
2.  CD4 count 
3. Viral load 
4. TLC  
5. Transfer in 
6. Other  
   
124.  Original regimen  1. 1a(30) 
2. 1a(40) 
3. 1b (30)  
4. 1b(40 
5. 1c 
6. 1d      
7. 1e 
8. 1f     
9. 1g 
10. 1h 
11.1i 
12. 1j 
125.  Was the Regimen 
modified before switch to 
second line changed? 
1. Yes                        2. No  If No to  
126.  How many times was it 
modified? 
1. Once 2. Two times 3. Three times    
127.  When was it modified?  
1st------/-------/---------------(DD/MM/YY) 
 
2nd------/--------/-------------(DD/MM/YY) 
 
 
3rd-------/-------/---------------( DD/MM/YY) 
128.  New regimen 1.  1st _____ 
 
2. 2nd_____ 3. 3rd_____    
129.  Reason for modification  1st 1. Side effects            2. TB                   3. Pregnancy                             4. Others 
2nd 1. Side effects            2. TB                   3. Pregnancy                             4. Others 
3rd 1. Side effects            2. TB                   3. Pregnancy                             4. Others 
130.   Opportunistic infections 
during first line treatment  
  
  OI-------------------                                    Date  --------------                                    OI--------------------                                      Date 
  OI--------------------                                    Date--------------                                    OI--------------------                                     Date------------- 
  OI--------------------                                      Date-------------                                   OI--------------------                                       Date------------- 
  OI--------------------                                       Date------------- 
131.  TB treatment history 
during first line treatment 
2. Yes      2. No 3. Not recorded  
If yes date -----------------             Treatment outcome-------------- 
     
132.  Date  the regimen 
changed to second line  
   
-----/-----/--------    (DD/MM/YY)  
 
133.  Reason for switch 1. Clinical failure 2. Immunologic failure 3. Virologic 
failure 
4. Drug toxicity Other(specify 
134.  Viral load at switch  
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Part III: Follow-up variables after switch to second line ART 
 
 
Date  
 
Wei
ght  
 
F.  
Statu
s  
 
WHO 
stage  
 
TB 
screen 
(P/N/o
n Rx) 
 
OIs 
INH CPT
/Adh
e(G,
F,P) 
ARV drug Hgb  CD4 
coun
t  
Last Status 
Ad
her
enc
e 
C
o
d
e
 
o
f 
re
g
im
en
  
Regim
en 
change
(Y/N) 
R. 
for 
cha
nge 
Side effect  
A
liv
e
  
T
x
.f
a
ilu
r
e
 
D
e
a
d
  
L
o
s
t 
to
 
fo
llo
w
 
u
p
  
T
ra
n
s
fe
r 
o
u
t 
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
1. **stage IV defining OI--------------------------Date-------------- 
2. **stage IV defining OI--------------------------Date--------------- 
3. **stage IV defining OI--------------------------Date-------------- 
4. **stage IV defining OI--------------------------Date-------------- 
Collected by: Name ____________________________ Signature ____________Date ________________ 
Supervised by: Name ___________________________ Signature ____________ Date _______________  
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Annex 2 . ART regimens 
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